Seeking Alpha
 

Medtronic plc (MDT)

- NYSE
  • Tue, Jun. 2, 8:00 AM
    • Medtronic (NYSE:MDT) fiscal Q4 results ($M): Revenues: 7,304 (+60.0%); Cardiac Rhythm & Heart Failure: 1,398 (+3.9%); Coronary & Structural Heart: 792 (+1.1%); Aortic & Peripheral Vascular: 406 (+69.2%); Cardiac & Vascular Group: 2,596 (+9.6%); Minimally Invasive Therapies Group: 2,387; Surgical Solutions: 1,293; Patient Monitoring & Recovery: 1,094; Spine: 743 (-5.5%); Neuromodulation: 518 (+1.0%); Surgical Technologies: 461 (+5.3%); Neurovascular: 132; Restorative Therapies: 1,854 (+6.7%); Diabetes Group: 467 (+1.5%).
    • Net Income: -1 (-100.2%); EPS: 0.00 (-100.0%); CF Ops: 1,912 (+44.0%).
    • Fiscal 2016 Guidance: Revenue growth: 4 - 6%; Non-GAAP EPS: $4.30 - 4.40.
    • Fiscal Q1 Guidance: Non-GAAP EPS: $1.08 - 1.13.
    | Comment!
  • Tue, Jun. 2, 7:25 AM
    • Medtronic (NYSE:MDT): FQ4 EPS of $1.16 beats by $0.05.
    • Revenue of $7.3B (+59.7% Y/Y) beats by $110M.
    • Press Release
    | Comment!
  • Mon, Jun. 1, 5:30 PM
  • Tue, May 19, 9:03 AM
    • Medtronic (NYSE:MDT) preliminary Q4 results ($M): Total Revenues: 7,302 (+59.9%); Cardiac Rhythm & Heart Failure: 1,398 (+3.9%); Coronary & Structural Heart: 792 (+1.1%); Aortic & Peripheral Vascular: 406 (+69.2%); Cardiac & Vascular Group: 2,596 (+9.6%); Minimally Invasive Therapies Group: 2,385; Spine: 743 (-5.5%); Neuromodulation: 518 (+1.0%); Surgical Technologies: 461 (+5.3%); Neurovascular: 132; Restorative Therapies Group: 1,854 (+6.7%); Diabetes Group: 467 (+1.5%).
    • This is the first quarter that includes Covidien so final results will be reported two weeks later than normal on June 2.
    | 1 Comment
  • Tue, Feb. 17, 8:13 AM
    • Medtronic (NYSE:MDT) fiscal Q3 results ($M): Total Revenues: 4,318 (+3.7%); Cardiac Rhythm & HF: 1,269 (+7.2%), High Power: 650 (-0.8%), Low Power: 489 (+11.4%), AF & Other: 130 (+44.4%); Coronary & Structural Heart: 737 (+2.8%), Coronary: 407 (-6.7%), Structural Heart: 330 (+17.4%); Aortic & Peripheral Vascular: 218 (0.0%); Cardiac & Vascular Group: 2,224 (+5.0%); Spine: 740 (-0.5%), Core Spine: 543 (-2.0%), Interventional Spine: 75 (-2.6%), BMP: 122 (-0.5%); Neuromodulation: 487 (+1.9%); Surgical Technologies: 418 (+8.3%).
    • COGS: 1,128 (+7.4%); R&D Expense: 373 (+3.6%); SG&A Expense: 1,487 (+2.3%); Net Income: 977 (+28.2%); EPS: 0.98 (+30.7%); CF Ops: (+9.6%), Quick Assets: 17,231 (+26.1%).
    • Gross Profit: 3,190 (+2.5%); COGS: 26.1% (+3.6%); Gross Margin: 73.9% (-1.2%); Operating Earnings: 1,330 (+2.4%); Operating Earnings Yield: 30.8% (-1.3%); Net Earnings Yield: 22.6% (+23.6%).
    • CF Ops last three quarters: 310, 913, 1767.
    • Fiscal Q4 Guidance: Revenue growth: 4 - 6%.
    • Shares are up 3% premarket on increased volume.
    | Comment!
  • Tue, Feb. 17, 7:43 AM
    • Medtronic (NYSE:MDT): FQ3 EPS of $1.01 beats by $0.04.
    • Revenue of $4.32B (+3.8% Y/Y) beats by $70M.
    • Shares +0.12% PM.
    • Press Release
    | 2 Comments
  • Mon, Feb. 16, 5:30 PM
  • Wed, Feb. 11, 4:11 PM
    • Medtronic (NYSE:MDT) will report fiscal Q3 results on February 17 before the open. The conference call will begin at 7:00 am CT/8:00 am ET.
    • Consensus view is EPS of $0.97 on revenues of $4.3B.
    | Comment!
  • Thu, Jan. 22, 8:38 AM
    • Covidien (COV) FQ1 results: Revenues: $2,686M (+1.8%), Advanced Surgical: $928M (+8.8%), General Surgical: $385M (-5.6%), Surgical Solutions: $1,313M (+4.1%), Vascular Therapies: $428M (+0.7%), Respiratory and Patient Care: $945M (-0.8%); COGS: $1,042M (-3.2%); R&D Expense: $133M (+6.4%); SG&A: $865M (+1.8%); Operating Income: $648M (+22.0%); Net Income: $511M (+28.4%); EPS: $1.12 (+28.7%).
    • No guidance given.
    | Comment!
  • Thu, Jan. 22, 8:02 AM
    • Covidien (NYSE:COV): FQ1 EPS of $1.11 beats by $0.06.
    • Revenue of $2.69B (+1.9% Y/Y) misses by $30M.
    • Press Release
    | Comment!
  • Wed, Jan. 21, 5:30 PM
  • Nov. 18, 2014, 8:07 AM
    • Medtronic (NYSE:MDT) fiscal Q2 results ($M): Revenues: 4,366 (+4.1%); COGS: 1,142 (+4.8%); Operating Expenses: 1,881 (+3.9%); Net Income: 828 (-7.2%); EPS: 0.83 (-6.7%); CF Ops (6 mo.): 1,223 (-39.4%).
    • Revenue by group ($M): Cardiac Rhythm & Heart Failure: 1,320 (+3.7%); Coronary & Structural Heart: 743 (+4.9%); Aortic & Peripheral Vascular: 223 (+2.3%); Spine: 746 (unch); Neuromodulation: 494 (+3.1%); Surgical Technologies: 410 (+8.8%); Restorative Therapies: 1,650 (+3.0%); Diabetes Group: 430 (+9.4%).
    • 2015 Guidance: Revenue growth: 4 - 5% from 3 - 5%; non-GAAP EPS: $4.00 - 4.10 (unch).
    • Previously: Medtronic EPS and revenue in-line
    | 1 Comment
  • Nov. 18, 2014, 7:43 AM
    • Medtronic (NYSE:MDT): FQ2 EPS of $0.96 in-line.
    • Revenue of $4.37B (+4.3% Y/Y) in-line.
    • Press Release
    | Comment!
  • Nov. 17, 2014, 5:30 PM
  • Nov. 10, 2014, 4:47 PM
    • Medtronic (NYSE:MDT) will report fiscal Q2 results on November 18 before the open. The conference call will begin at 7:00 am CT/8:00 am ET.
    • Consensus view is EPS of $0.96 on revenues of $4.37B.
    | Comment!
  • Nov. 5, 2014, 9:27 AM
    • Covidien (COV -0.4%) FQ4 results: Revenues: $2,734M (+6.8%),Advanced Surgical: $951M (+17.1%), Surgical Solutions: $1,334M (+11.0%), Vascular Therapies: $426M (+3.1%), Respiratory and Patient Care: $974M (+3.1%); COGS: $1031M (-0.2%); R&D Expense: $149M (+2.1%); SG&A: $855M (+4.4%); Operating Income: $513M (+8.7%); Net Income: $517M (+39.0%); EPS: $1.13 (+41.3%).
    • FY 14 results : Revenues: $10,659M (+4.1%), Advanced Surgical: $3,553M (+11.5%), Surgical Solutions: $5,113M (+7.1%), Vascular Therapies: $1,677M (+1.5%), Respiratory and Patient Care: $3,869M (+1.6%); COGS: $4,173M (+4.6%); R&D Expense: $546M (+7.5%); SG&A: $3,580M (+9.2%); Operating Income: $1,992M (-6.6%); Net Income: $1,662M (-2.2%); EPS: $3.65 (+1.1%).
    • No guidance given.
    | Comment!
Visit Seeking Alpha's
MDT vs. ETF Alternatives
Company Description
Medtronic PLC is engaged in providing medical technology alleviating pain, restoring health, and extending life of people. It currently functions in three operating segments that manufacture and sell device-based medical therapies.